AR036321A1 - Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. - Google Patents

Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.

Info

Publication number
AR036321A1
AR036321A1 ARP000102569A ARP000102569A AR036321A1 AR 036321 A1 AR036321 A1 AR 036321A1 AR P000102569 A ARP000102569 A AR P000102569A AR P000102569 A ARP000102569 A AR P000102569A AR 036321 A1 AR036321 A1 AR 036321A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical formulation
dyscinesia
late appearance
melatonin
Prior art date
Application number
ARP000102569A
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of AR036321A1 publication Critical patent/AR036321A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

La presente se refiere al uso de melatonina en la elaboración de un medicamento para la prevención o tratamiento de síntomas de discinesia tardía en un paciente; y a una formulación farmacéutica que comprende una cantidad efectiva de al menos un compuesto neuroléptico, y melatonina en una cantidad efectiva para mejorar o prevenir el desarrollo de síntomas de discinesia tardía.
ARP000102569A 1999-05-27 2000-05-26 Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. AR036321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13017199A IL130171A (en) 1999-05-27 1999-05-27 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines

Publications (1)

Publication Number Publication Date
AR036321A1 true AR036321A1 (es) 2004-09-01

Family

ID=11072852

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102569A AR036321A1 (es) 1999-05-27 2000-05-26 Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.

Country Status (30)

Country Link
US (1) US6566389B1 (es)
EP (1) EP1183024A4 (es)
JP (1) JP2003500446A (es)
KR (1) KR20020015329A (es)
CN (1) CN1176652C (es)
AR (1) AR036321A1 (es)
AU (1) AU775520B2 (es)
BG (1) BG106234A (es)
BR (1) BR0017329A (es)
CA (1) CA2374129A1 (es)
CZ (1) CZ20014190A3 (es)
EA (1) EA004057B1 (es)
EE (1) EE200100623A (es)
HK (2) HK1046089A1 (es)
HU (1) HUP0201405A3 (es)
IL (1) IL130171A (es)
IS (1) IS6172A (es)
MX (1) MXPA01012040A (es)
NO (1) NO319421B1 (es)
NZ (1) NZ515866A (es)
PE (1) PE20010129A1 (es)
PL (1) PL351885A1 (es)
SK (1) SK16402001A3 (es)
TN (1) TNSN00117A1 (es)
TR (1) TR200103418T2 (es)
TW (1) TWI236906B (es)
UA (1) UA71968C2 (es)
UY (1) UY26171A1 (es)
WO (1) WO2000072843A1 (es)
ZA (1) ZA200110436B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7799817B2 (en) * 2004-02-20 2010-09-21 Lifescape Biosciences Inc Compositions and methods for sleep regulation
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
US7494674B2 (en) 2006-09-22 2009-02-24 Lapointe Andrew T Nutraceutical with tart cherries and method of treatment therewith
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691324A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
AUPO588297A0 (en) * 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production

Also Published As

Publication number Publication date
WO2000072843A1 (en) 2000-12-07
IS6172A (is) 2001-11-22
EA200101240A1 (ru) 2002-06-27
AU4775600A (en) 2000-12-18
CA2374129A1 (en) 2000-12-07
TNSN00117A1 (fr) 2005-11-10
CN1352556A (zh) 2002-06-05
JP2003500446A (ja) 2003-01-07
MXPA01012040A (es) 2003-09-04
EE200100623A (et) 2003-02-17
CZ20014190A3 (cs) 2002-05-15
IL130171A (en) 2004-06-01
HK1047048A1 (en) 2003-02-07
PL351885A1 (en) 2003-06-30
EP1183024A4 (en) 2007-02-28
US6566389B1 (en) 2003-05-20
NZ515866A (en) 2003-05-30
BG106234A (bg) 2002-08-30
ZA200110436B (en) 2004-03-31
NO319421B1 (no) 2005-08-08
HK1047048B (zh) 2005-05-27
TR200103418T2 (tr) 2004-12-21
NO20015738D0 (no) 2001-11-26
NO20015738L (no) 2002-01-25
PE20010129A1 (es) 2001-04-27
HUP0201405A2 (en) 2002-08-28
HK1046089A1 (zh) 2002-12-27
AU775520B2 (en) 2004-08-05
BR0017329A (pt) 2003-07-29
KR20020015329A (ko) 2002-02-27
EP1183024A1 (en) 2002-03-06
TWI236906B (en) 2005-08-01
HUP0201405A3 (en) 2003-11-28
SK16402001A3 (sk) 2002-04-04
UA71968C2 (en) 2005-01-17
CN1176652C (zh) 2004-11-24
IL130171A0 (en) 2000-06-01
UY26171A1 (es) 2000-12-29
EA004057B1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
BR0015188A (pt) Composições farmacêuticas
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
CU23367A3 (es) Formulación de moxifloxacino con sal común
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
BRPI0406634A (pt) Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica
NO20051261L (no) Morfin-6-glukuronidsalt
CA2385755A1 (en) Prevention of colorectal cancer
TW200509909A (en) Use of organic compounds
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
DE602004014964D1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
AR045177A1 (es) Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave
BRPI0410507A (pt) combinação de substáncias ativas, uso de uma combinação de substáncias e processo para o tratamento do abuso do álcool e/ou da dependência de álcool
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome

Legal Events

Date Code Title Description
FA Abandonment or withdrawal